Literature DB >> 11672924

Induction of specific CD8+ memory T cells and long lasting protection following immunization with Salmonella typhimurium expressing a lymphocytic choriomeningitis MHC class I-restricted epitope.

H Shams1, F Poblete, H Rüssmann, J E Galán, R O Donis.   

Abstract

Numerous studies have shown the potential of Salmonella typhimurium as a vector for delivery of heterologous proteins for vaccination against other pathogens. Earlier studies showed that the inefficient elicitation of MHC class I-restricted responses could limit the use of S. typhimurium as a heterologous antigen delivery vector for vaccination. We recently developed an approach to overcome this limitation by using a bacterial-encoded specialized protein secretion system, termed type III, to deliver proteins into the class I antigen presenting pathways. Thus, peptides of interest fused to proteins bearing the type III secretion signal, which can elicit protective CTL responses. Because protective immunity is usually assessed a few weeks after vaccination, there is a paucity of information regarding duration of protective immunity induced by this system. We show here that mice immunized orally with S. typhimurium vectors expressing a MHC class I-restricted epitope of the lymphocytic choriomeningitis virus (LCMV) nucleoprotein developed specific antiviral CTL responses. CD8+ T cells were found to be necessary for this CTL activity against targets presenting the LCMV epitope. The survival of mice challenged with lethal doses of LCMV 60 or 135 days after vaccination was as complete as the survival of mice challenged 2 weeks after immunization with the same vectors. By demonstrating their ability to induce prolonged protective immunity after oral delivery, S. typhimurium vectors have met an essential requirement in support of their development as vectors for heterologous vaccination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672924     DOI: 10.1016/s0264-410x(01)00363-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Live attenuated Salmonella vaccines against Mycobacterium tuberculosis with antigen delivery via the type III secretion system.

Authors:  María Dolores Juárez-Rodríguez; Lourdes T Arteaga-Cortés; Rebin Kader; Roy Curtiss; Josephine E Clark-Curtiss
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  Optimization of the delivery of heterologous proteins by the Salmonella enterica serovar Typhimurium type III secretion system for vaccine development.

Authors:  Li-Mei Chen; Gabriel Briones; Ruben O Donis; Jorge E Galán
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

3.  In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.

Authors:  Hiroyoshi Nishikawa; Eiichi Sato; Gabriel Briones; Li-Mei Chen; Mitsutoshi Matsuo; Yasuhiro Nagata; Gerd Ritter; Elke Jäger; Hideki Nomura; Shigeto Kondo; Isao Tawara; Takuma Kato; Hiroshi Shiku; Lloyd J Old; Jorge E Galán; Sacha Gnjatic
Journal:  J Clin Invest       Date:  2006-06-22       Impact factor: 14.808

4.  Immunogenicity of recombinant attenuated Salmonella enterica serovar Typhimurium vaccine strains carrying a gene that encodes Eimeria tenella antigen SO7.

Authors:  Vjollca Konjufca; Mark Jenkins; Shifeng Wang; Maria Dolores Juarez-Rodriguez; Roy Curtiss
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

Review 5.  New technologies in developing recombinant attenuated Salmonella vaccine vectors.

Authors:  Shifeng Wang; Qingke Kong; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-11-08       Impact factor: 3.738

6.  A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge.

Authors:  Devon J Shedlock; Kendra T Talbott; Christina Cress; Bernadette Ferraro; Steven Tuyishme; Karthik Mallilankaraman; Neil J Cisper; Matthew P Morrow; Stephan J Wu; Omkar U Kawalekar; Amir S Khan; Niranjan Y Sardesai; Karuppiah Muthumani; Hao Shen; David B Weiner
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

Review 7.  New technologies in using recombinant attenuated Salmonella vaccine vectors.

Authors:  Roy Curtiss; Wei Xin; Yuhua Li; Wei Kong; Soo-Young Wanda; Bronwyn Gunn; Shifeng Wang
Journal:  Crit Rev Immunol       Date:  2010       Impact factor: 2.214

8.  A recombinant attenuated Salmonella enterica serovar Typhimurium vaccine encoding Eimeria acervulina antigen offers protection against E. acervulina challenge.

Authors:  Vjollca Konjufca; Soo-Young Wanda; Mark C Jenkins; Roy Curtiss
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

9.  A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy.

Authors:  Audrey Le Gouëllec; Xavier Chauchet; David Laurin; Caroline Aspord; Julien Verove; Yan Wang; Charlotte Genestet; Candice Trocme; Mitra Ahmadi; Sandrine Martin; Alexis Broisat; François Cretin; Catherine Ghezzi; Benoit Polack; Joël Plumas; Bertrand Toussaint
Journal:  Mol Ther       Date:  2013-03-26       Impact factor: 11.454

10.  Novel cancer vaccine based on genes of Salmonella pathogenicity island 2.

Authors:  Guosheng Xiong; Mohamed I Husseiny; Liping Song; Anat Erdreich-Epstein; Gregory M Shackleford; Robert C Seeger; Daniela Jäckel; Michael Hensel; Leonid S Metelitsa
Journal:  Int J Cancer       Date:  2010-06-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.